CTRI/2009/091/000276已完成3 期
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib versus Sorafenib as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma - CA182-033
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,714
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Histologic or cytologic confirmed diagnosis of HCC. Advanced HCC
- •Disease not eligible for surgical and / or locoregional therapies
- •Progressive disease after surgical and / or locoregional therapies
- •Child-Pugh Class A
- •ECOG performance status 0-1
- •Adequate hematologic, hepatic, and renal function
排除标准
- •Prior use of any systemic anti-cancer chemotherapy, immunotherapy or molecular targeted agents for HCC
- •History of active cardiac disease
- •Thrombotic or embolic events within the past 6 months
- •Any other hemorrhage/bleeding event >= CTCAE Grade 3 within 4 weeks except for esophageal or gastric varices
- •Inability to swallow tablets or untreated malabsorption syndrome
研究者
相似试验
进行中（未招募）
1 期
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib plus BestSupportive Care (BSC) versus Placebo plus BSC in Subjects with Advanced Hepatocellular Carcinoma (HCC) who have Failed or are Intolerant to Sorafenib: The BRISK PS Study.Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (v1.0, dated 12-Sep-2008)/// Estudio fase III, aleatorizado, doble ciego, multicéntrico, de brivanib más mejor tratamiento de soporte (BSC) frente a placebo más BSC en sujetos con carcinoma hepatocelular (CHC) avanzado con fracaso o intolerancia a sorafenib: estudio BRISK PSEnmienda número 01 - sobre muestras de sangre para farmacogenética - Específica de centro - BRISK PS studyAdvanced Hepatocellular Carcinoma/// Carcinoma Hepatocelular avanzadoMedDRA version: 9.1Level: LLTClassification code 10019829Term: Hepatocellular carcinoma recurrentMedDRA version: 9.1Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableEUCTR2008-005084-34-ESBristol Myers Squibb International Corporation680
进行中（未招募）
不适用
Phase III, First Line Advanced Hepatocellular Carcinoma (HCC)advanced hepatocellular carcinomaMedDRA version: 14.1Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-003533-24-DEBristol-Myers Squibb International Corporation1,800
进行中（未招募）
1 期
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib versus Sorafenibas First-line Treatment in Patients with Advanced Hepatocellular Carcinoma (The BRISK FL Study) - BRISK FL StudyEUCTR2008-003533-24-FRBristol Myers Squibb International Corporation1,665
已完成
不适用
Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC) GRANITE-1-C160 CardiaCardiaC160PER-105-09OVARTIS BIOSCIENSES PERU S.A.,11
进行中（未招募）
不适用
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib versus Sorafenib as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma. - BRISK FL StudyHepatocellular carcinoma non-resectableMedDRA version: 12.0Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableEUCTR2008-003533-24-ITBristol Myers Squibb International Corporation1,800